NEW YORK, May 10, 2017 /PRNewswire/ --
The iShares Nasdaq Biotechnology ETF, the largest biotechnology exchange traded fund by assets, is up nearly 13% year-to-date,
indicating biotechnology is playing a pivotal role in the broader healthcare sector's resurgence, according to a report on ETF
Trends. This morning, Stock-Callers.com takes a closer look at four companies to see how they have fared over the last few
trading sessions: Bioverativ Inc. (NASDAQ: BIVV), Zosano Pharma Corp. (NASDAQ: ZSAN), MannKind Corp. (NASDAQ: MNKD), and Ocera
Therapeutics Inc. (NASDAQ: OCRX). You can access our complimentary research reports on these stocks now at:
http://stock-callers.com/registration
Bioverativ
Shares in Waltham, Massachusetts headquartered Bioverativ Inc. rose 0.74%, ending Tuesday's
trading session at $55.95. The stock recorded a trading volume of 823,798 shares. The Company's
shares have surged 25.90% over the last three months and 24.39% on an YTD basis. The stock is trading 3.32% and 7.53% above its
50-day and 200-day moving averages, respectively. Moreover, shares of Bioverativ, which focuses on the research, discovery,
development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the US and
Japan, have a Relative Strength Index (RSI) of 48.72.
On April 24 th, 2017, research firm Gabelli & Co. downgraded the Company's stock
rating from 'Buy' to 'Hold'.
On May 03 rd, 2017, Bioverativ reported financial results for Q1 2017. Key financial
results included Q1 2017 revenues of $259.1 million, GAAP net income of $69.3 million; non-GAAP net income of $74.0 million; GAAP earnings per share
(EPS) of $0.64; non-GAAP EPS of $0.68; and net cash flows from
operations of $108.2 million. Visit us today and download your complete report on BIVV for free
at: http://stock-callers.com/registration/?symbol=BIVV
Zosano Pharma
Fremont, California headquartered Zosano Pharma Corp.'s stock declined 2.56%, closing the day
at $1.45 with a total trading volume of 774,997 shares. The Company's shares have advanced 22.88%
in the previous three months and 85.90% since the start of this year. The stock is trading 17.42% above its 200-day moving
average. Additionally, shares of Zosano Pharma, which develops a proprietary intracutaneous delivery system to administer drugs
through the skin for rapid symptom relief to patients, have an RSI of 33.81. The complimentary research report on ZSAN can be
accessed at: http://stock-callers.com/registration/?symbol=ZSAN
MannKind
On Tuesday, shares in Valencia, California-based MannKind Corp. recorded a trading volume of
9.21 million shares, which was above their three months average volume of 2.51 million shares. The stock ended the day 10.89%
higher at $1.12. The Company's shares have advanced 118.20% in the previous three months and 75.91%
on an YTD basis. The stock is trading above its 200-day moving average by 32.17%. Furthermore, shares of MannKind, which focuses
on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the US, have an RSI of
50.39.
On May 04 th, 2017, MannKind and One Drop announced
that they have signed a memorandum of understanding to enter into a collaborative agreement that would extend the latter's
subscription service and digital health platform, which currently provides unlimited blood glucose testing supplies and 24/7 live
in-app support from diabetes experts by adding Afrezza as a rapid-acting insulin offering. Register for free on
Stock-Callers.com and download the PDF research report on MNKD at: http://stock-callers.com/registration/?symbol=MNKD
Ocera Therapeutics
Palo Alto, California headquartered Ocera Therapeutics Inc.'s stock jumped 4.92%, finishing
yesterday's session at $1.28 with a total trading volume of 570,655 shares. The Company's shares
have advanced 4.07% in the last one month and 132.73%% in the previous three months. The stock is trading above its 50-day moving
average by 6.04%. Additionally, shares of Ocera Therapeutics, which operates as a clinical stage biopharmaceutical company, have
an RSI of 50.00. Get free access to your research report on OCRX at: http://stock-callers.com/registration/?symbol=OCRX
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you ' re
a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between
09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA